Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CollPlant Biotechnologies Ltd. stock logo
CLGN
CollPlant Biotechnologies
$1.93
$2.25
$1.55
$6.00
$22.11M1.2411,502 shs1,905 shs
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
$2.00
+1.5%
$1.80
$1.42
$12.33
$73.35M1.4597,248 shs455,089 shs
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
$4.82
+2.8%
$4.61
$4.01
$9.33
$79.27M1.3207,546 shs74,105 shs
Zynex, Inc. stock logo
ZYXI
Zynex
$2.59
+8.4%
$2.26
$1.66
$10.62
$78.32M0.7161,585 shs300,934 shs
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CollPlant Biotechnologies Ltd. stock logo
CLGN
CollPlant Biotechnologies
0.00%+10.92%-13.65%-43.47%-66.50%
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
0.00%-4.83%+5.35%-0.51%-82.09%
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
0.00%-0.85%-1.05%-7.86%-23.11%
Zynex, Inc. stock logo
ZYXI
Zynex
0.00%+1.27%-0.83%-68.34%-77.28%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
CollPlant Biotechnologies Ltd. stock logo
CLGN
CollPlant Biotechnologies
3.3926 of 5 stars
3.75.00.00.03.80.01.3
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
3.8594 of 5 stars
3.32.00.04.33.40.01.3
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
2.7569 of 5 stars
3.64.00.00.02.50.01.3
Zynex, Inc. stock logo
ZYXI
Zynex
3.0369 of 5 stars
3.21.00.00.01.72.53.1
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CollPlant Biotechnologies Ltd. stock logo
CLGN
CollPlant Biotechnologies
3.33
Buy$12.50547.67% Upside
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
2.50
Moderate Buy$9.75387.50% Upside
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
3.25
Buy$11.67142.05% Upside
Zynex, Inc. stock logo
ZYXI
Zynex
2.33
Hold$6.00131.66% Upside

Current Analyst Ratings Breakdown

Latest CLGN, SRTS, INO, and ZYXI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/19/2025
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$14.00 ➝ $10.00
5/14/2025
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSector Perform ➝ Sector Perform$5.00 ➝ $5.00
5/14/2025
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$15.00 ➝ $13.00
4/30/2025
Zynex, Inc. stock logo
ZYXI
Zynex
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Perform ➝ Sector Perform$5.00 ➝ $4.00
4/30/2025
Zynex, Inc. stock logo
ZYXI
Zynex
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$15.00 ➝ $8.00
4/15/2025
Zynex, Inc. stock logo
ZYXI
Zynex
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSector Perform ➝ Sector Perform
4/4/2025
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$12.00 ➝ $12.00
3/27/2025
CollPlant Biotechnologies Ltd. stock logo
CLGN
CollPlant Biotechnologies
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$14.00 ➝ $14.00
3/19/2025
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Perform ➝ Sector Perform$6.00 ➝ $5.00
3/19/2025
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$3.00 ➝ $3.00
3/12/2025
Zynex, Inc. stock logo
ZYXI
Zynex
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$17.00 ➝ $15.00
(Data available from 5/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CollPlant Biotechnologies Ltd. stock logo
CLGN
CollPlant Biotechnologies
$515K42.93N/AN/A$2.47 per share0.78
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
$283.10K259.09N/AN/A$5.16 per share0.39
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
$39.49M2.01$0.05 per share96.29$2.98 per share1.62
Zynex, Inc. stock logo
ZYXI
Zynex
$172.40M0.45$0.14 per share18.01$1.36 per share1.90
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CollPlant Biotechnologies Ltd. stock logo
CLGN
CollPlant Biotechnologies
-$7.02M-$1.46N/AN/AN/A-2,680.00%-77.05%-61.43%5/27/2025 (Estimated)
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
-$135.12M-$3.19N/AN/AN/AN/A-118.17%-83.47%8/14/2025 (Estimated)
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
$6.65M$0.1012.0520.96N/A15.90%12.60%11.38%8/14/2025 (Estimated)
Zynex, Inc. stock logo
ZYXI
Zynex
$9.73M-$0.2417.275.51N/A2.49%13.05%3.78%7/23/2025 (Estimated)

Latest CLGN, SRTS, INO, and ZYXI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
6/4/2025Q1 2025
CollPlant Biotechnologies Ltd. stock logo
CLGN
CollPlant Biotechnologies
-$0.37N/AN/AN/A$9.76 millionN/A
5/15/2025Q1 2025
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
$0.04-$0.16-$0.20-$0.16$7.23 million$8.34 million
5/13/2025Q1 2025
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
-$0.74-$0.51+$0.23-$0.51$0.01 million$0.07 million
4/28/2025Q1 2025
Zynex, Inc. stock logo
ZYXI
Zynex
-$0.24-$0.33-$0.09-$0.33$30.83 million$26.58 million
3/26/2025Q4 2024
CollPlant Biotechnologies Ltd. stock logo
CLGN
CollPlant Biotechnologies
-$0.42-$0.34+$0.08-$0.34$0.36 million$0.17 million
3/18/2025Q4 2024
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
-$0.87-$0.69+$0.18-$0.60$0.03 million$0.12 million
3/11/2025Q4 2024
Zynex, Inc. stock logo
ZYXI
Zynex
$0.09-$0.02-$0.11-$0.02$53.65 million$45.98 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
CollPlant Biotechnologies Ltd. stock logo
CLGN
CollPlant Biotechnologies
N/AN/AN/AN/AN/A
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
N/AN/AN/AN/AN/A
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
N/AN/AN/AN/AN/A
Zynex, Inc. stock logo
ZYXI
Zynex
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CollPlant Biotechnologies Ltd. stock logo
CLGN
CollPlant Biotechnologies
N/A
5.38
5.23
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
N/A
3.88
3.88
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
N/A
10.52
7.89
Zynex, Inc. stock logo
ZYXI
Zynex
1.66
3.94
3.15

Institutional Ownership

CompanyInstitutional Ownership
CollPlant Biotechnologies Ltd. stock logo
CLGN
CollPlant Biotechnologies
21.69%
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
26.79%
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
25.30%
Zynex, Inc. stock logo
ZYXI
Zynex
29.68%

Insider Ownership

CompanyInsider Ownership
CollPlant Biotechnologies Ltd. stock logo
CLGN
CollPlant Biotechnologies
9.60%
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
2.30%
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
8.90%
Zynex, Inc. stock logo
ZYXI
Zynex
49.28%
CompanyEmployeesShares OutstandingFree FloatOptionable
CollPlant Biotechnologies Ltd. stock logo
CLGN
CollPlant Biotechnologies
7011.46 million10.36 millionOptionable
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
32036.67 million25.45 millionOptionable
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
4016.45 million14.85 millionOptionable
Zynex, Inc. stock logo
ZYXI
Zynex
77030.24 million15.25 millionOptionable

Recent News About These Companies

Here’s Why Zynex (ZYXI) Fell in Q1

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
CollPlant Biotechnologies stock logo

CollPlant Biotechnologies NASDAQ:CLGN

$1.94 +0.01 (+0.47%)
As of 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds; as well as develops injectable breast implants and 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures. It has collaboration agreements with Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; International Society for Biofabrication; AbbVie; and STEMCELL Technologies. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. The company was founded in 2004 and is headquartered in Rehovot, Israel.

Inovio Pharmaceuticals stock logo

Inovio Pharmaceuticals NASDAQ:INO

$2.00 +0.03 (+1.52%)
Closing price 04:00 PM Eastern
Extended Trading
$2.00 +0.00 (+0.25%)
As of 07:29 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

Sensus Healthcare stock logo

Sensus Healthcare NASDAQ:SRTS

$4.82 +0.13 (+2.77%)
Closing price 04:00 PM Eastern
Extended Trading
$4.82 +0.00 (+0.10%)
As of 06:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sensus Healthcare, Inc., a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides SRT-100 Plus; Sentinel service program, which offers its customers protection for their systems; and Transdermal Infusion system, a biophysical alternative to infuse high weight molecule modalities into the dermis for medical and aesthetic purposes without the use of needles. In addition, it sells disposable lead shielding replacements; and disposable radiation safety items, such as aprons and eye shields, ultrasound probe film, and disposable applicator tips to treat various sized lesions and various areas of the body. Further, the company distributes laser devices, which includes applications for hair removal, vascular lesions, acne treatment, skin toning, and skin rejuvenation, as well as epidermal pigment removal for spots, freckles, and tattoos. It markets its products primarily to private dermatology practices, and radiation oncologists in both private and hospital settings. Sensus Healthcare, Inc. was incorporated in 2010 and is headquartered in Boca Raton, Florida.

Zynex stock logo

Zynex NASDAQ:ZYXI

$2.59 +0.20 (+8.37%)
Closing price 04:00 PM Eastern
Extended Trading
$2.58 0.00 (-0.19%)
As of 07:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Zynex, Inc., together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, and braces for rehabilitation support. Further, it offers Zynex Fluid Monitoring System (CM-1500); Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser-based noninvasive co-oximeter; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; hemodynamic monitoring and intravascular volume monitoring; and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.